Factors that have impact on treatment options and prognosis for BC include the immunohistochemical status of estrogen receptors (ER), progesterone receptors (PR) and the human epidermal growth factor receptor 2 (HER2) [4]. This evidence concerns the gene ESR1 and breast cancer.